IO Biotech's co-founder presented advancements in cancer vaccines at the 2025 AACR Annual Meeting, highlighting innovative therapeutic strategies. IO Biotech, a clinical-stage biopharmaceutical ...
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...
Additionally, Mads Hald Andersen, DMSc, PhD, Director of the Center for Cancer Immune Therapy (CCIT) and scientific co-founder of IO Biotech, will be chairing and speaking at an education session on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results